Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of July 2026, with the report dated July 15, 2026. The document serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity compensation matters rather than financial performance results.
Material Changes
The primary material event reported is the grant of employee warrants on July 14, 2026:
- Warrant Grant: The Board of Directors granted an aggregate of 14,060 warrants to certain employees.
- Exercise Price: Set at US $265.57 per share, reflecting the closing price on the date of grant.
- Vesting Schedule: 25% vests on the one-year anniversary; the remaining 75% vests monthly at a rate of 1/36th thereafter, subject to continued service and potential acceleration upon exit events.
- Articles of Association: The Company amended its Articles of Association to facilitate this grant.
- Remaining Pool: Following this grant, 1,539,503 warrants remain available for future issuance.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document is limited to the disclosure of the warrant grant and the incorporation of the Articles of Association by reference.
Investor Verification Checklist
- Verify the total number of outstanding warrants and the remaining pool size (1,539,503) against the latest equity plan disclosures.
- Confirm the exercise price of $265.57 aligns with the market price on July 14, 2026.
- Review the amended Articles of Association (Exhibit 1.1) for any changes to the warrant pool limits or vesting terms.
- Assess the potential dilution impact of the 14,060 newly granted warrants relative to the total share count.